Bruker (BRKR) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Bruker (NASDAQ:BRKR) posted its quarterly earnings results on Thursday. The medical research company reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.02, Bloomberg Earnings reports. The firm had revenue of $530.50 million during the quarter, compared to analyst estimates of $506.74 million. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The company’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.46 earnings per share. Bruker updated its FY18 guidance to $1.34 to $1.38 EPS.

Bruker (BRKR) traded down $1.54 on Thursday, hitting $31.62. 1,040,000 shares of the stock traded hands, compared to its average volume of 484,321. Bruker has a twelve month low of $21.83 and a twelve month high of $36.53. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. The company has a market capitalization of $4,920.00, a PE ratio of 33.64, a P/E/G ratio of 2.50 and a beta of 1.05.

Several analysts have recently weighed in on BRKR shares. Zacks Investment Research lowered shares of Bruker from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Citigroup raised their price objective on shares of Bruker from $29.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Cowen reaffirmed a “hold” rating and set a $29.00 price objective on shares of Bruker in a report on Friday, November 3rd. Bank of America raised shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price objective for the company in a report on Friday, November 3rd. Finally, JPMorgan Chase & Co. raised shares of Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price objective for the company in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $32.38.

An institutional investor recently raised its position in Bruker stock. The Manufacturers Life Insurance Company increased its stake in shares of Bruker Co. (NASDAQ:BRKR) by 7.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,003 shares of the medical research company’s stock after purchasing an additional 331 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in Bruker were worth $144,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 65.63% of the company’s stock.

WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/08/bruker-brkr-issues-quarterly-earnings-results-beats-estimates-by-0-02-eps.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Earnings History for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply